Table 2 The relationship between the level of LP-PLA2 and seriousness of clinical Presentation

N

294

192

330

240

Age (years)

60.63 ± 11.96

66.00 ± 13.66

64.80 ± 10.99

62.05 ± 11.58

Male(%)

204 (69.4)

150 (78.1)

252 (76.4)

186 (77.5)

Smoking(%)

84 (28.6)

66 (34.3)

138 (41.8)

108 (45)

Hypertension(%)

168 (57.1)

120 (62.5)

252 (76.4)

120 (50)

Diabetes (%)

54 (18.4)

60 (31.2)

84 (25.5)

72 (30)

FBG (mmol/L)^a

5.35 (4.39–8.56)

6.13 (4.69–10.36)

6.14 (4.72–10.38)

6.23 (4.56–10.42)

Lp(a) (mmol/L)^a

230.39 (112.06–428.32)

282.16 (115.22–652.36)

308.20 (122.08–721.12)

322.03 (130.06–732.16)

TC (mmol/L)

4.40 ± 1.13

4.25 ± 1.13

4.31 ± 1.19

4.53 ± 1.15

TG (mmol/L)

1.52 ± 0.97

1.65 ± 0.96

1.64 ± 0.96

1.65 ± 0.69

LDL-C (mmol/L)

2.82 ± 0.93

2.65 ± 0.89

2.65 ± 1.02

2.94 ± 0.88

HDL-C (mmol/L)

1.17 ± 0.28

1.11 ± 0.22

1.05 ± 0.27*

1.04 ± 0.24*

Lp-PLA2(ng/ml) ^a

172.83 (92.35–296.42)

193.84 (102.35–372.35)

263.95 (172.32–396.45)*^&

311.45 (185.24–412.35)*^&